Hyperbaric Oxygen Therapy for Filler-Induced Vascular Occlusion

Key Takeaways

• Filler-induced vascular occlusion is a rare but potentially serious complication of dermal filler injection in which arterial blood flow to the skin or other tissues becomes reduced or obstructed.
• The immediate priority is restoration of perfusion. With hyaluronic acid fillers, prompt treatment with hyaluronidase remains the mainstay of management.¹
• Hyperbaric oxygen therapy (HBOT) does not dissolve filler and should not replace appropriate emergency treatment. Its role is complementary: to increase oxygen delivery to threatened tissue while circulation is impaired and during recovery following reperfusion.^{2 3}
• HBOT may also reduce tissue oedema, modify ischaemia-reperfusion injury and support angiogenesis, fibroblast function and wound healing.^{4 5}
• Published experience with HBOT in filler-induced vascular occlusion has grown considerably. A 2026 scoping review identified 24 publications describing its use, predominantly case reports and small case series, usually alongside hyaluronidase and other treatments.³
• The broader evidence for HBOT in compromised and ischaemic soft tissue is stronger. A 2026 systematic review included 24 comparative studies involving 2,246 patients, including 13 randomised controlled trials, although certainty of evidence varied between outcomes.⁶
• Treatment appears most rational when started early, while tissue remains potentially viable, although published cases also describe recovery after delayed referral.³
• Sudden visual loss or neurological symptoms following filler injection constitute a separate medical emergency and require immediate hospital assessment. HBOT must never delay ophthalmological or stroke management.⁷

Quick Summary

Dermal fillers are widely used and serious vascular complications are uncommon. When vascular occlusion does occur, however, interruption of arterial flow can produce a rapidly evolving ischaemic injury.

For hyaluronic acid filler, the most important early intervention is appropriate administration of hyaluronidase to break down the filler and facilitate restoration of perfusion. Current clinical guidance emphasises prompt recognition and treatment when a cutaneous vascular occlusion is suspected.¹

Hyperbaric oxygen therapy addresses a different part of the problem.

HBOT does not remove or dissolve the obstructing filler. Instead, it substantially increases the amount of oxygen dissolved directly in plasma and markedly increases tissue oxygen tensions. This increases the diffusion gradient between functioning vessels and hypoxic tissue and may help deliver oxygen to areas receiving inadequate red-cell blood flow. HBOT also produces physiological effects relevant to acute ischaemic injury, including reduction of oedema, modulation of inflammatory and ischaemia-reperfusion pathways and support of subsequent tissue repair.^{4 5}

HBOT is therefore best considered as an adjunct to reperfusion treatment rather than an alternative to it.

In hyaluronic acid filler occlusion, the combination is physiologically attractive: hyaluronidase addresses the obstructing material, while HBOT supports oxygen-starved tissue during the period in which perfusion remains compromised and while the microcirculation recovers.^{2 3}

Care Strategy

The management of filler-induced vascular occlusion begins with the clinician responsible for the filler complication. A detailed discussion of injection techniques and emergency hyaluronidase protocols is outside the scope of this article, but the essential principle is that suspected vascular compromise requires urgent assessment and treatment.

For hyaluronic acid filler, hyaluronidase remains the principal reversal treatment and should not be delayed while arranging HBOT.¹

From a hyperbaric perspective, HBOT may be particularly relevant where there is persistent mottling or ischaemic discolouration after initial treatment, where a substantial vascular territory is affected, where presentation has been delayed, where tissue injury continues to evolve despite reversal treatment, or where a non-hyaluronic-acid filler is involved and no specific dissolving agent is available.^{2 3}

Once skin necrosis or ulceration has developed, HBOT may still have a role in supporting viable but hypoxic tissue around the injury and in subsequent wound healing. It cannot, however, restore tissue that has already undergone irreversible necrosis.

Any visual disturbance, ophthalmoplegia, severe ocular pain or neurological symptom requires immediate emergency hospital assessment. Filler-related retinal, ophthalmic or cerebral embolisation should not be treated as a routine cutaneous filler complication, and HBOT should never delay emergency transfer or specialist management.⁷

What Happens During Filler-Induced Vascular Occlusion?

Vascular compromise may develop when filler is inadvertently introduced into an artery and mechanically obstructs blood flow. Other mechanisms may contribute, including vascular compression, vasospasm, endothelial injury, platelet activation and secondary thrombosis.^{1 2}

The result is a mismatch between oxygen supply and tissue demand.

Initially, cells attempt to adapt to reduced oxygen availability. As ischaemia progresses, oxidative metabolism becomes increasingly impaired, ATP production declines and normal cellular homeostasis becomes difficult to maintain. If adequate perfusion is not restored, reversible cellular dysfunction progresses towards irreversible tissue injury and necrosis.

Clinically, the process may manifest as blanching followed by mottled or livedoid discolouration, abnormal capillary refill, pain, sensory disturbance and, in more advanced cases, blistering, epidermal breakdown or necrosis.¹

The severity of injury depends not simply on whether an artery has been obstructed. It also depends on the vessel involved, the extent of obstruction, available collateral circulation, duration of ischaemia and metabolic requirements of the affected tissue.

This is particularly important when considering HBOT because an affected vascular territory is unlikely to be physiologically uniform. Some tissue may be severely underperfused, while surrounding areas retain varying degrees of collateral flow.

It is this threatened but still viable ischaemic penumbra that represents the principal potential target for tissue-salvage therapies.

What Is Hyperbaric Oxygen Therapy?

Hyperbaric oxygen therapy involves breathing near-pure oxygen under increased atmospheric pressure inside a medical hyperbaric chamber.

At normal pressure, most oxygen is carried by haemoglobin, with only a small amount dissolved in plasma. Under hyperbaric conditions, substantially more oxygen dissolves directly into plasma, producing very high arterial and tissue oxygen tensions.⁴

This increases the diffusion of oxygen from functioning vessels into surrounding hypoxic tissue, including areas with impaired but not completely absent blood flow.

HBOT does not reopen an obstructed artery and cannot compensate for tissue with no perfusion or collateral circulation. Restoration of blood flow therefore remains the primary objective, while HBOT provides additional oxygen support to threatened but viable tissue.

.

How May HBOT Protect Tissue After a Filler Vascular Occlusion?

Increasing Oxygen Delivery to the Ischaemic Penumbra

By markedly increasing dissolved plasma oxygen, HBOT increases the diffusion gradient from functioning capillaries towards hypoxic tissue.⁴

This may be particularly important at the margins of an occluded vascular territory, where blood flow is impaired but collateral circulation remains present.^{4 5}

Reduction of Tissue Oedema

Ischaemic tissue frequently becomes oedematous.

Endothelial injury and inflammatory changes increase vascular permeability, allowing fluid to accumulate in the interstitial space. This can further compromise the microcirculation and increase the distance oxygen must travel between functioning capillaries and affected cells.

HBOT produces vasoconstriction in normally perfused tissue while simultaneously maintaining very high oxygen availability. The net effect can be reduction of tissue oedema without the degree of tissue hypoxia that would normally accompany vasoconstriction.^{4 5}

This can be particularly relevant in already compromised tissue, where swelling may further impair microvascular perfusion.

Reducing oedema may therefore improve the local tissue environment by reducing diffusion distance and limiting an additional component of microvascular compromise.

Ischaemia-Reperfusion Injury

Restoration of circulation is essential, but reperfusion itself is biologically complex.

Following a period of ischaemia, reintroduction of oxygenated blood can initiate a cascade involving reactive oxygen and nitrogen species, inflammatory signalling, endothelial dysfunction, leukocyte activation and further microvascular injury.

This process is known as ischaemia-reperfusion injury.

It may partly explain why tissue can continue to deteriorate despite apparent improvement in macroscopic blood flow.

HBOT has been investigated extensively in experimental and clinical models of ischaemia-reperfusion injury. Although it might seem counterintuitive to administer additional oxygen during a process associated with oxidative stress, therapeutic hyperoxia is not simply an uncontrolled excess of oxygen.

Intermittent hyperoxia influences redox-sensitive cellular signalling and may alter neutrophil-endothelial interactions, inflammatory responses and cellular defence mechanisms.^{4 5}

This is potentially relevant following successful hyaluronidase treatment.

Hyaluronidase may begin to address the obstruction, while HBOT may provide tissue oxygen support during both the preceding period of ischaemia and the subsequent phase of reperfusion and microvascular recovery.

Angiogenesis and Microvascular Repair

The biological effects of HBOT extend beyond the period during which the patient is inside the chamber.

Repeated intermittent hyperoxia influences oxygen-sensitive cellular pathways involved in angiogenesis and vascular repair. Experimental and clinical research has demonstrated effects on vascular endothelial growth factor signalling and mobilisation of circulating progenitor cells involved in neovascularisation.⁴

These mechanisms are unlikely to be the dominant therapeutic effect during the earliest hours of acute filler ischaemia, when preservation of cellular viability is the immediate objective.

They may, however, become increasingly relevant during the following days as damaged dermal and subcutaneous microcirculation begins to recover.

Fibroblasts, Collagen Formation and Wound Healing

Adequate oxygen availability is fundamental to normal wound healing.

Fibroblast proliferation and collagen formation are oxygen-dependent. Oxygen is also required for collagen hydroxylation and maturation, epithelial repair and normal oxidative killing by neutrophils.^{4 5}

This provides another potential role for HBOT after the acute vascular event.

Where tissue has suffered substantial but non-lethal injury, or where partial skin breakdown has occurred, the therapeutic objective evolves from immediate tissue salvage towards supporting wound repair.

In compromised grafts and flaps, proposed benefits of HBOT include increased tissue oxygenation, improved fibroblast function, neovascularisation and attenuation of ischaemia-reperfusion injury.⁵

Although a compromised surgical flap is not the same condition as filler-induced vascular occlusion, these mechanisms are highly relevant to the shared problem of potentially reversible tissue hypoxia.

Why HBOT and Hyaluronidase Are Complementary

One of the most important points when discussing HBOT for filler vascular complications is that it should not be positioned as competing with hyaluronidase.

The two treatments address different aspects of the injury.

In a hyaluronic-acid filler occlusion, hyaluronidase targets the cause by breaking down hyaluronic acid. HBOT targets an important consequence: tissue oxygen deprivation.

There may also be a period between successful administration of hyaluronidase and complete restoration of effective microcirculatory function. Secondary oedema, vasospasm, endothelial dysfunction, platelet activation and reperfusion processes do not necessarily disappear immediately when the filler begins to dissolve.

This provides a strong physiological argument for combining rapid reversal treatment with early tissue oxygen support where clinically significant ischaemia persists.^{2 3}

The published literature largely reflects this approach. In the cases reviewed by Ramirez and colleagues, HBOT was generally used as part of multimodal management rather than as a standalone intervention.³

From a hyperbaric medicine perspective, this is probably the most appropriate way to conceptualise treatment: restore perfusion wherever possible, while simultaneously supporting the oxygen requirements of threatened tissue.

Clinical Evidence for HBOT in Filler-Induced Vascular Occlusion

The filler-specific evidence has historically consisted predominantly of case reports and small case series, but the literature has gradually expanded.

One of the earlier reports was published by Darling and colleagues in 2014. The authors described two cases of impending tissue necrosis following injections involving hyaluronic acid and calcium hydroxylapatite in which HBOT formed part of multimodal treatment.⁸

A further case reported by Uittenbogaard and colleagues involved persistent dermal ischaemia following calcium hydroxylapatite filler. Despite initial medical treatment, pain, numbness and skin discolouration persisted. The patient subsequently received ten HBOT sessions consisting of 90 minutes of oxygen at 2.5 ATA. The authors reported resolution of the discolouration and neurological symptoms, with complete tissue healing and a favourable cosmetic outcome at six months.⁹

This case is particularly interesting from a hyperbaric perspective because calcium hydroxylapatite cannot be enzymatically dissolved with hyaluronidase in the same way as hyaluronic acid. It illustrates the potential importance of supportive tissue-salvage strategies where direct enzymatic reversal of the filler is unavailable.

Madero and colleagues published a dedicated review of HBOT in filler-induced vascular occlusion in 2024. The authors examined hyperoxygenation, vascular and inflammatory effects, angiogenesis and hypoxia-related pathways, while emphasising that HBOT should remain adjunctive and that optimal treatment dosing and timing have not yet been established.²

More recently, Stevens and Lewis reported a case of suspected upper-lip vascular occlusion following hyaluronic acid filler. Hyaluronidase was administered initially in the cosmetic clinic and again in the emergency department, but symptoms and signs of vascular compromise persisted. The patient subsequently received nine hyperbaric treatments over seven days, with a favourable clinical outcome.¹⁰

These individual cases cannot establish the independent efficacy of HBOT because patients generally received several interventions and there were no untreated comparison groups. They do, however, demonstrate a recurring clinical pattern in which HBOT has been used to support persistently ischaemic tissue following appropriate initial vascular management.

The 2026 Scoping Review

The most comprehensive review specifically examining HBOT in filler-induced vascular occlusion was published by Ramirez and colleagues in 2026.³

The authors reviewed literature published between 2011 and May 2025 and identified 24 publications describing the use of HBOT in filler-induced vascular occlusion.

The evidence consisted predominantly of individual case reports and small case series. HBOT was generally administered as an adjunct to hyaluronidase and other vascular or wound-management strategies.

Treatment protocols varied substantially. Reported treatment pressures ranged broadly from approximately 2.0 to 3.0 ATA, with oxygen exposures generally lasting 60 to 120 minutes.³

Numerous reports described substantial or complete recovery of compromised skin. Some patients received HBOT relatively early, while others were referred after a delay and nevertheless demonstrated improvement. These findings are encouraging, but they need to be interpreted appropriately.

There are currently no high-quality randomised controlled trials demonstrating the independent effect of HBOT specifically in filler-induced vascular occlusion.

Because HBOT has usually been combined with hyaluronidase and other treatments, it is difficult to determine how much of the observed recovery resulted from enzymatic reversal, spontaneous or collateral reperfusion, HBOT itself, or the combined effect of several interventions.

The authors therefore concluded that HBOT is a promising adjunctive intervention but that prospective research and greater standardisation of treatment protocols are needed.³

Evidence From Compromised Soft Tissue, Grafts and Flaps

The filler-specific literature should also be considered alongside the broader evidence for HBOT in compromised and hypoxic soft tissue.

This is relevant because the therapeutic target is similar: tissue in which viability is threatened by inadequate oxygen delivery.

In 2026, Carter and colleagues published a systematic review evaluating HBOT in severe soft-tissue injuries and in patients undergoing or being considered for skin graft and flap reconstruction.⁶

The review included 25 reports from 24 comparative studies involving 2,246 patients, including 13 randomised controlled trials and 11 non-randomised comparative studies. Most included studies favoured HBOT for healing outcomes, and meta-analysis of four randomised trials evaluating flap or graft survival demonstrated a statistically significant overall treatment effect. The authors issued a number of strong and conditional recommendations for HBOT in selected severe soft-tissue, trauma, flap and graft settings.⁶. This evidence is substantially stronger than the direct evidence available for filler-induced vascular occlusion. However, it remains indirect evidence.

A surgically compromised flap or traumatic soft-tissue injury is not identical to an artery obstructed by dermal filler. The anatomy, mechanism of vascular compromise and opportunities for direct reversal are different. Nevertheless, the underlying physiological problems overlap considerably: reduced perfusion, tissue hypoxia, oedema, microvascular dysfunction and ischaemia-reperfusion injury.^{5 6}

The established evidence for HBOT in compromised tissues therefore provides a clinically relevant framework for considering its adjunctive use in filler-associated tissue ischaemia.

Timing: When Should HBOT Be Started?

In acute ischaemic injury, the therapeutic objective is to support tissue before reversible cellular injury progresses to irreversible necrosis.

For this reason, where HBOT is considered appropriate, early treatment is biologically preferable.

The same principle is recognised in compromised grafts and flaps, where hyperbaric treatment is generally most useful when initiated once surgically correctable causes of vascular compromise have been addressed and while threatened tissue remains viable.⁵

There is, however, no validated number of hours after a filler vascular occlusion beyond which HBOT suddenly becomes ineffective. The clinical literature reviewed by Ramirez and colleagues includes delayed referrals in which patients still demonstrated improvement following HBOT.³

Early treatment should be encouraged, but delayed presentation should not automatically be interpreted as meaning that HBOT can no longer be useful.

The more relevant question is whether hypoxic but potentially viable tissue remains.

Where irreversible full-thickness necrosis has already occurred, HBOT cannot resurrect dead tissue. However, the surrounding wound margins, deeper tissues and microcirculation may still be compromised and potentially salvageable.

In clinical practice, the decision should therefore be based on tissue viability, the evolution of the injury and the overall clinical picture rather than an arbitrary time cut-off.

Typical HBOT Treatment Approach

Published HBOT protocols for filler-induced vascular occlusion vary, but treatment is commonly delivered at approximately 2.0–2.5 ATA for 90–120 minutes.^{2 3 5}

A course of around 10 sessions may be considered a reasonable practical approach based on the published experience, although the total number should be individualised according to the severity of tissue ischaemia and clinical response.³

Earlier treatment is generally preferable while threatened tissue remains viable, with the course reviewed and adjusted according to tissue recovery.

What About Visual Loss Following Filler Injection?

Visual loss following facial filler injection is a fundamentally different level of emergency.

Filler entering arterial branches communicating with the ophthalmic circulation can cause retinal or ophthalmic artery occlusion and, in some cases, cerebral vascular complications.

Any sudden alteration in vision after facial filler requires immediate emergency transfer and specialist ophthalmological assessment. Neurological symptoms additionally require an appropriate stroke pathway.⁷

HBOT has a physiological rationale in conventional central retinal artery occlusion because markedly increased plasma oxygen tension may allow oxygen from the choroidal circulation to diffuse towards the hypoxic inner retina.

Filler-related retinal vascular occlusion is more complicated, however, because embolic material may obstruct the ophthalmic artery or multiple arterial branches and may compromise both retinal and choroidal circulation.

A 2026 evidence-informed algorithm for hyaluronic-acid filler-related visual loss includes HBOT among potential in-hospital adjunctive interventions, but the authors emphasise that evidence for treatment of filler-related visual loss remains predominantly derived from case reports and small case series.⁷

HBOT must therefore never delay emergency transfer, ophthalmological assessment, stroke assessment or specialist reperfusion treatment.

Visual complications should be managed within an appropriate multidisciplinary hospital pathway.

Non-Hyaluronic-Acid Fillers

The potential role of HBOT is particularly relevant when vascular compromise follows a filler that cannot be enzymatically dissolved.

Unlike hyaluronic acid, fillers such as calcium hydroxylapatite have no equivalent enzymatic reversal treatment. Published cases have described favourable outcomes with adjunctive HBOT in this setting, although the evidence remains observational.^{3 8 9}

Supporting oxygen delivery to threatened tissue may therefore be particularly valuable when direct dissolution of the obstructing material is not possible.

Safety and Side Effects of HBOT

HBOT is generally well tolerated when delivered in a medical hyperbaric facility following appropriate assessment.

The most common side effects are ear or sinus pressure, with less common risks including barotrauma, temporary visual changes and, rarely, oxygen toxicity seizures.⁴

Untreated pneumothorax is the principal absolute contraindication. Treatment should therefore be prescribed and supervised by clinicians trained in hyperbaric medicine.

Conclusion

Filler-induced vascular occlusion is an acute ischaemic injury in which rapid restoration of perfusion remains the priority, including prompt hyaluronidase treatment for hyaluronic-acid filler.¹

HBOT can increase oxygen delivery to threatened tissue and support recovery through effects on oedema, ischaemia-reperfusion injury and wound healing.^{4 5}

Although filler-specific evidence remains largely observational, the growing clinical literature and broader evidence from compromised soft tissue support HBOT as a rational adjunctive tissue-salvage therapy in selected cases.

Where significant cutaneous ischaemia persists following appropriate initial treatment, early hyperbaric assessment should be considered.

Frequently Asked Questions

Can HBOT dissolve filler?

No.

Hyperbaric oxygen does not dissolve dermal filler.

For hyaluronic-acid vascular occlusion, hyaluronidase is used to break down the filler. HBOT acts on tissue oxygenation and the subsequent ischaemic injury rather than directly removing the obstruction.^{1 2}

Should HBOT be used instead of hyaluronidase?

No.

Where a hyaluronic-acid vascular occlusion is suspected, appropriate hyaluronidase treatment should not be delayed.

HBOT should be considered adjunctive to treatment directed at restoring vascular perfusion.^{1 2 3}

When should HBOT be started?

When significant tissue ischaemia persists and HBOT is considered clinically appropriate, referral should ideally occur early.

There is no validated filler-specific time window beyond which treatment has no value. Published cases include patients treated after delayed presentation who nevertheless demonstrated clinical improvement.³

The important consideration is whether potentially viable but hypoxic tissue remains.

How many HBOT sessions are required?

There is no standard number.

Published filler cases have used a wide variety of treatment courses. The 2026 scoping review reported pressures of approximately 2.0 to 3.0 ATA and oxygen exposures generally between 60 and 120 minutes, with the total number of treatments varying according to the clinical circumstances.³

Treatment should therefore be individually prescribed and reviewed according to clinical response.

Can HBOT still help once skin breakdown has occurred?

Potentially.

HBOT cannot restore tissue that is already irreversibly necrotic, but surrounding and deeper tissues may remain hypoxic and potentially salvageable.

Its effects on tissue oxygenation, oedema, angiogenesis, fibroblast function and wound repair may also remain relevant during subsequent healing.^{4 5}

More advanced wounds require appropriate wound-care and, where necessary, plastic-surgical or other specialist assessment alongside consideration of HBOT.

Is HBOT useful when the filler is not hyaluronic acid?

Potentially.

This may be an especially interesting application because many non-HA fillers cannot be directly dissolved.

Published cases have described HBOT following calcium hydroxylapatite-associated vascular compromise with favourable outcomes, although the evidence remains limited to uncontrolled clinical observations.^{3 8 9}

Does HBOT guarantee that there will be no scarring?

No.

The eventual cosmetic result depends on the severity, extent and duration of the initial ischaemia and whether irreversible tissue injury develops before adequate circulation and oxygenation are restored.

HBOT aims to maximise survival and healing of threatened tissue. It cannot guarantee complete recovery or the absence of subsequent pigmentation or scarring.

References